# A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

> **NCT04761198** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mereo BioPharma** · enrollment: 76 (actual)

## Conditions studied

- Solid Tumor, Adult
- Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** Etigilimab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04761198
- **Lead sponsor:** Mereo BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-23
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04761198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04761198, "A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04761198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*